Computer image. iPhone image.
Accelerating the development of pet medicine
Using our proprietary technology, we enhance each facet of the pharmaceutical process.
We do this to focus on developing products for unmet needs not being addressed by other companies.
Pipeline
In response to the limited number of approved treatments available, veterinarians must often prescribe off-label products intended to treat other conditions or species.
Our portfolio focuses on meeting underserved needs rather than creating redundant versions of products already in use. Take a look at what we have in the pipeline and see Anivive’s impact.
14
Total Therapeutics
5
Endocrine
4
Middle-Stage
1
Early-Stage
3
Oncologic
2
Infectious
4
Other
Oncologic
1
Late-Stage
2
Middle-Stage
Infectious
1
Late-Stage
1
Middle-Stage
Cardiovascular
1
Middle-Stage
Ophthalmic
1
Middle-Stage
Dental
1
Middle-Stage
Gastrointestinal
1
Early-Stage
Endocrine
Oncologic
Infectious
Cardiovascular
Ophthalmic
Dental
Gastrointestinal
<
>
How We Do It
Our suite of software solutions enhances every facet of the therapeutic development process in order to reduce the time and resources needed to bring revolutionary products to approval.
The majority of devastating pet diseases lack approved therapies because the development process is so costly and time-consuming.
Discovery
Our evaluation tool de-risks and identifies potential therapeutic candidates at a faster rate than our competitors.
Partner Relations
We’ve streamlined and improved the way we care for, communicate with, and collaborate alongside our partners. We’ve created a central hub that simplifies how we manage cumbersome paperwork and administration, creating better business relationships that focus on innovation.
Development
We’ve reimagined the way the clinical trial process works. AniviveTrial expedites patient enrollment, simplifies data management, and minimizes human error, while creating a seamless user experience for both the pet owner and the clinical team.
Commercialization
coming soon
Anivive’s future sales and distribution portal for approved Anivive therapeutics.
<
>
See Our Innovations In Action
College of Medicine, Tucson
National Institutes of Health Awards $4.8 Million to UA Valley Fever Center for Excellence to Develop Vaccine
Read More Decorative Arrow
Karyopharm Therapeutics
Karyopharm and Anivive Lifesciences Sign Exclusive Global License Agreement for Verdinexor for Animal Health Applications
Read More Decorative Arrow